Key facts
- LUPKYNIS associated with a 53% reduction in risk of renal-related event or death.
- Analysis presented at EULAR 2026 Congress.
- Data from the AURORA 1 Phase 3 study of lupus nephritis patients.
- Hazard ratio for renal-related event or death was 0.47 (p=0.0007).
- LUPKYNIS showed reduced risk for death, treatment failure, and worsening proteinuria.
Aurinia Pharmaceuticals Inc. announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS® in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress. The analysis, based on the safety population of 356 patients (178 on LUPKYNIS and 178 on placebo), indicates that LUPKYNIS was associated with a statistically significant 53% reduction in the risk of a renal-related event or death. The hazard ratio for this outcome was 0.47, with a p-value of 0.0007. Hazard ratios favored treatment with LUPKYNIS for individual components of the composite endpoint, including death (HR=0.19, an 81% reduction in risk; p=0.0929), treatment failure (HR=0.45, a 55% reduction in risk; p=0.0062), and worsening proteinuria (HR=0.22, a 78% reduction in risk; p<0.0001).